5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia

Mayo Clinic Proceedings

Volumn 91, Issue 12, 2016, Pages 1717-1726

  Wallner, Lauren P ^a,b   DiBello, Julia R ^c   Li, Bonnie H ^b   Van Den Eeden, Stephen K ^d   Weinmann, Sheila ^e   Ritzwoller, Debra P ^b   Abell, Jill E ^f   D'Agostino, Ralph ^g   Loo, Ronald K ^b   Aaronson, David S ^d   Richert Boe, Kathryn ^e   Horwitz, Ralph I ^h,i   Jacobsen, Steven J ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b KAISER PERMANENTE   (United States)

^c GLAXOSMITHKLINE   (United States)

^d DIVISION OF RESEARCH   (United States)

^e Center for Health Research Kaiser Permanente Northwest   (Portugal)

^f Janssen   (United States)

^g WAKE FOREST UNIVERSITY   (United States)

^h TEMPLE UNIVERSITY   (United States)

ⁱ INSTITUTE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGED; CANCER MORTALITY; CASE CONTROL STUDY; COHORT ANALYSIS; COMMUNITY CARE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EXPOSURE; GLEASON SCORE; HUMAN; INTEGRATED HEALTH CARE SYSTEM; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; PROSTATE CANCER; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT DURATION; CHEMICALLY INDUCED; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; ODDS RATIO; PROSTATE TUMOR; PROSTATIC HYPERPLASIA; RISK FACTOR; TREATMENT OUTCOME;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-ANTAGONISTS; AGED; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 85003017718     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2016.07.023     Document Type: Conference Paper

References (24)

1. 1 Thompson, I.M., Goodman, P.J., Tangen, C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349:3 (2003), 215–224.
2. 2 Andriole, G.L., Bostwick, D.G., Brawley, O.W., et al., REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:13 (2010), 1192–1202.
3. 3 Rubin, M.A., Kantoff, P.W., Prevention of prostate cancer with finasteride. N Engl J Med 349:16 (2003), 1569–1572.
4. 4 Scardino, P.T., The prevention of prostate cancer — the dilemma continues. N Engl J Med 349:3 (2003), 297–299.
5. 5 Zuger, A., A big study yields big questions. N Engl J Med 349:3 (2003), 213–214.
6. 6 Figg, W.D., Thompson, I.M., Effect of 5α-reductase inhibitor use on mortality from prostate cancer. JAMA Oncol 1:3 (2015), 321–322.
7. 7 LeFevre, M., A role for finasteride in the prevention of prostate cancer?. N Engl J Med 369:7 (2013), 670–671.
8. 8 Azoulay, L., Eberg, M., Benayoun, S., Pollak, M., 5A-reductase inhibitors and the risk of cancer-related mortality in men with prostate cancer. JAMA Oncol 1:3 (2015), 314–320.
9. 9 Preston, M.A., Wilson, K.M., Markt, S.C., et al. 5alpha-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med 174:8 (2014), 1301–1307.
10. 10 Thompson, I.M. Jr., Goodman, P.J., Tangen, C.M., et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med 369:7 (2013), 603–610.
11. 11 Koebnick, C., Langer-Gould, A.M., Gould, M.K., et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J 16:3 (2012), 37–41.
12. 12 Ross, T.R., Ng, D., Brown, J.S., et al. The HMO Research Network Virtual Data Warehouse: a public data model to support collaboration. EGEMS (Wash DC), 2(1), 2014, 1049.
13. 13 Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:5 (1987), 373–383.
14. 14 Fine, J.P., Gray, R.J., A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:446 (1999), 496–509.
15. 15 Grambsch, P.M., Therneau, T.M., Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:3 (1994), 515–526.
16. 16 Murtola, T.J., Karppa, E.K., Taari, K., Talala, K., Tammela, T.L., Auvinen, A., 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial. Int J Cancer 138:12 (2016), 2820–2828.
17. 17 FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. http://www.fda.gov/Drugs/DrugSafety/ucm258314.htm. Accessed June 30, 2015.
18. 18 Andriole, G.L., Humphrey, P.A., Serfling, R.J., Grubb, R.L., High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artifact?. J Natl Cancer Inst 99:18 (2007), 1355–1356.
19. 19 Goodman, P.J., Thompson, I.M. Jr., Tangen, C.M., Crowley, J.J., Ford, L.G., Coltman, C.A. Jr., The prostate cancer prevention trial: design, biases and interpretation of study results. J Urol 175:6 (2006), 2234–2242.
20. 20 Redman, M.W., Tangen, C.M., Goodman, P.J., Lucia, M.S., Coltman, C.A. Jr., Thompson, I.M., Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) 1:3 (2008), 174–181.
21. 21 Lucia, M.S., Darke, A.K., Goodman, P.J., et al. Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila) 1:3 (2008), 167–173.
22. 22 Thompson, I.M., Chi, C., Ankerst, D.P., et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98:16 (2006), 1128–1133.
23. 23 Cohen, Y.C., Liu, K.S., Heyden, N.L., et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99:18 (2007), 1366–1374.
24. 24 Suissa, S., Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 16:3 (2007), 241–249.